Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Don England who wrote (1077)	5/8/2000 9:29:00 PM
From: david james	Respond to of 52153

Any press releases on the research presented have been "embargoed" until the meeting. So we could see quite a week of announcements regarding breakthroughs once the meeting begins. And this is the big meeting of the year, where the scientists are hoping to not only impress the public, but their colleagues as well - a much tougher audience. _____________________________________________________ IMPORTANT ADVANCES IN CANCER RESEARCH TO BE PRESENTED AT THE ASCO 2000 ANNUAL MEETING More than 20,000 cancer professionals from around the world will gather at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the Ernest N. Morial Convention Center in New Orleans from May 20-23, 2000. Beginning Saturday, May 20th, ASCO will hold seven media briefings featuring significant research being presented at the Annual Meeting, and reviewing important areas of concern in the field of cancer care. All research is embargoed until the date and time of scientific presentation. asco.org I am expecting something good from CEGE regarding their vaccine for prostate cancer. The company has been referring to this meeting for the last couple months. But I am sure that is true of several companies involved in cancer research.

To: Don England who wrote (1077)	5/9/2000 10:21:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Don, A lot depends on the psychological state of the biotech market when ASCO happens. Some times we've seen a run-up in stocks that are presenting ahead of similar meetings, some times we've seen brief pops when the PR is released, and last year, if I recall correctly, we saw not much of anything. If the market doesn't do anything crazy in the run-up to the meeting, I would be moderately optimistic that we'll see at the very least some nice pops. Here's the ASCO PR: -- ASCO Announces Press Program for Meeting in New Orleans, LA, May 20-23, 2000 -- -- Meeting Features New Developments in Breast Cancer Therapy, Treating Hot Flashes, and Molecular Treatment Strategies -- More than 20,000 cancer professionals from around the world will gather at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO) at the Ernest N. Morial Convention Center in New Orleans from May 20-23, 2000. ASCO?s Plenary Session will feature important breakthroughs in breast, lung, kidney, and stomach cancers, as well as a new, non-estrogenic drug to reduce hot flashes. ASCO press conferences will highlight new findings in the treatment of breast cancer, efforts to improve quality of life for cancer patients, new molecular targets and strategies for cancer treatment, advances in lung cancer care, and the results of major, practice-changing, clinical trials. In addition, ASCO President, Joseph S. Bailes, MD, will discuss the society?s major new initiative to assess the quality of cancer care in the U.S., and ASCO will hold a special session for media to address the current state of clinical cancer research ? including cost, safety and recent developments in high-dose chemotherapy for breast cancer. Over 2,600 abstracts have been accepted this year, more than ever before, for presentation in the plenary, integrated, oral, poster and general poster sessions, and for publication in the program proceedings book. Scientific research will be presented on each of the four days of the meeting, in addition to physician education sessions. Peter